NOVEL PDE4 INHIBITORS

摘要

PDE4 inhibitors, pharmaceutical compositions including the inhibitors, and methods of treatment using the inhibitors are disclosed. The compounds are illustrated by Formulas 1-9 in the specification. The compounds can be used to treat a variety of disorders mediated by phosphodiesterase, and TNF-a, including asthma, chronic bronchitis, chronic obstructive pulmonary disease, arthritis, respiratory distress syndrome, allergic rhinitis, neurogenic inflammation, pain, rheumatoid arthritis, central nervous system disorders, cardiovascular disorders, and tumor progression.